Richard Samuel FinnMD
Dr. Richard Finn is an Assistant Professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/ Oncology. He was an undergraduate at UCLA where he was involved with early laboratory studies investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer with Dr. Dennis Slamon.
He participated in the pre-clinical studies that defined the clinical candidate that eventually humanized and became the FDA approved agent trastuzumab (Herceptin). He went on to medical school at USC then returned to UCLA for his clinical training in Internal Medicine and then Hematology/ Oncology.